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Thermoresponsive Polysarcosine-Based Nanoparticles
 
Huayang Yua, Nicola Ingramb, Jason V. Rowleya, Sam Parkinsonc, David C. Greena, Nicholas J. Warrenc 
and Paul D. Thornton*a
Polysarcosine holds great promise as an alternative to poly(ethylene glycol) for use within both biomedical and non-
biomedical applications owing to its hydrophilicity and non-cytoxicity, amongst other features. The grafting of a limited 
quantity of N-(2-hydroxypropyl)methacrylamide) to polysarcosine, for instance 3.5% of the total copolymer in terms of the 
number of repeat units, has a profound effect on the properties of the copolymer formed; polymer self-assembly to yield 
thermoreponsive nanoparticles can now be realised. Such nanoaparticles are non-cytotoxic against a range of human breast 
cancer cell lines, able to withhold the therapeutic compound doxorubicin, and allow pronounced doxorubicin release in 
response to subtle thermal stimulation. This research informs of how the straightforward modification of polysarcosine with 
a nominal molar amount of poly(N-(2-hydroxypropyl)methacrylamide) can yield stimuli-responsive polymers that are 
suitable for use within controlled release applications.
     
Introduction
Polypeptoids can form effective components of biomaterials 
owing to their variable and controllable chemical functionality, 
thermal stability, non-cytotoxicity, potential degradability and 
low immunogenicity.1 In particular, polysarcosine (PSar) holds 
outstanding promise as a biomedical polymer due to its 
hydrophilicity, the controllable manner in which its synthesis 
proceeds,2,3 and the exclusive H-bond acceptor repeat units 
that offer it resistance to protein fouling.4 Consequently, PSar 
offers a real alternative to poly(ethylene glycol) (PEG) for 
numerous applications,5 including its use as a non-fouling 
coating,6 and therapeutic protein conjugation.7 The precise 
control over PSar synthesis has enabled the accurate synthesis 
of block copolymers that contain PSar conjugated to other 
polypeptoids,8-10 )9C"):11,12 tertiary amine-
containing molecules,13 PEG,14 and poly(amino 
acids)/polyamides.15-17
There has been much recent interest in the application of 
PSar for the controlled release of therapeutic compounds. In 
such instances, PSar habitually forms the hydrophilic, and non-
fouling, section of an amphiphilic block copolymer capable of 
forming nanoparticles in aqueous solution.18 Recent literature 
examples of PSar-based systems that have broad potential as 
drug delivery/controlled release vehicles include the creation of 
amphiphilic block copolymers composed of PSar and )9C"
caprolactone) that are capable of undergoing thermally-
mediated self-assembly to bear a range of (nano)carriers,19 
amphiphilic star-like copolymers consisting of PSar and Boc-
protected polylysine, that undergo degradation in response to 
elevated glutathione concentration,20 and very recently the 
creation of E"&
%")
' antibody drug 
conjugates (ADC) that feature PSar as a hydrophobicity masking 
entity within an ADC drug-linker platform.21 Recent work within 
our laboratory includes the creation of PSar-containing block 
copolymers, polymerised from a therapeutic initiator, that form 
enzyme-responsive nanoparticles,22 and the creation of 
poly(amino acid)-poly(ester) conjugates synthesised by 
glucosamine-initiated ring-opening polymerisation, that are 
susceptible to acid-mediated degradation.23 Such promising 
results ensure that additional investigation into the use of PSar 
as a component within controlled release systems is of value.
The water-solubility of PSar ensures that polymer 
modification must be realised in order to create PSar-based 
nanoparticles in aqueous solution. Reversible addition-
fragmentation chain-transfer (RAFT) polymerisation is an 
extensively exploited technique for the generation of 
amphiphilic block copolymers, and offers the opportunity to 
graft non-water-soluble oilgomers/polymers to PSar, enabling 
the creation of thermoresponsive polymer nanoparticles.24 
Confirmation of nanoparticle formation, as RAFT 
polymerisation proceeds, may be achieved in situ using dynamic 
light scattering (DLS) measurements. Here, nanoparticle 
dimensions and dispersity are determined non-destructively, 
under normal conditions (i.e. without drying, extraction etc.), 
offering a convenient initial guide of the suitability of the block 
a.School of Chemistry, University of Leeds, Leeds, United Kingdom, LS2 9JT, UK.
b.Leeds Institute of Biomedical and Clinical Sciences, Wellcome Trust Brenner 
Building, St Jamess University Hospital, Leeds, LS9 7TF, UK.
c. School of Chemical and Process Engineering, University of Leeds, Leeds, LS2 9JT, 
UK.
 Electronic Supplementary Information (ESI) available: 1H NMR spectra, FTIR 
spectra, DLS spectra and cytotoxicity assay details.. See DOI: 10.1039/x0xx00000x
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copolymer synthesised as a potential nanocarrier. The RAFT 
polymerisation of N-(2-hydroxypropyl)methacrylamide) 
(HPMA) generates a non-immunogenic and non-toxic 
polymer,25,26 and a well-established route to PHPMA-based 
polymer nanoparticles is via RAFT aqueous dispersion 
polymerisation. Frequently, nanoparticles are produced by 
conducting this process in the presence of a PEG macro RAFT 
agent,27 although recently, OReilly and co-workers described 
the preparation of a range of PSar-b-PHPMA copolymers 
capable of forming various morphologies dependant on the 
copolymer composition.28 The number of non-biodegradable 
PHPMA repeat units within the block copolymer ranged 
between 100 and 400, and dictated the outcome of PSar59-b-
PHPMAn self-assembly in aqueous solution. Although the drug 
delivery capabilities, and the thermoresponse, of the 
nanoparticles created were not reported, such materials may 
be considered appropriate for use in drug delivery applications 
if the molecular weight of the non-degradable PHPMA section 
within the copolymer can be limited to enable its clearance 
from the body, post-deployment. 
We report the creation of thermoresponsive PSar-b-PHPMA 
nanoparticles designed to contain highly constrained molar 
amounts of PHPMA within the block copolymer composition. 
Nanoparticle formation was monitored in situ, and the polymer 
deemed most suitable for use a potential drug delivery vehicle 
was advanced to doxorubicin (Dox) loading and release studies. 
The thermoresponse of the polymers was demonstrated by 
pronounced Dox release as a consequence of a moderate 
increase in solution temperature. Accordingly, the efficacy of 
the loaded nanoparticles against a range of breast cancer cell 
types was evaluated, and revealed that Dox-loaded 
nanoparticles were lethal against all breast cancer cell types 
tested, in marked contrast to unloaded non-cytotoxic 
nanoparticles. The reported polymers are thus highly-suited to 
the encapsulation and thermally-triggered release of molecular 
cargo, which may be applied for the eradication of breast cancer 
cells. 
Experimental
Materials and Methods
Sarcosine (98 %) and N-boc-ethylenediamine hydrochloride (98 %) 
were purchased from Alfa Aesar. K"$
 (98 %), trifluoroacetic acid 
(99%, extra pure), chloroform (99.9 %, extra dry over molecular 
sieve, stabilised, acroseal), tetrahydrofuran (99.5 %, Extra Dry, over 
Molecular Sieves) and buffer solution pH 5 (acetate buffer) were 
obtained from ACROS Organics. Triphosgene, triethylamine 
anhydrous and doxorubicin hydrochloride were obtained from 
Fluorochem. n-Hexane, ethanol absolute and dichloromethane were 
purchased from VWR International. Dimethyl sulfoxide (99.80 % D) 
was purchased from EURISO-TOP. Diethyl ether (analytical reagent 
grade) and triethylamine were obtained from Fisher Scientific. All 
other chemicals were obtained from Sigma-Aldrich
Chemical structures and functional groups were identified by 
Nuclear Magnetic Resonance (NMR, Bruker AVANCE III HD-400) and 
Attenuated Total Reflection (ATR-PLATINUM) Fourier Transform 
Infrared Spectroscopy (FTIR, BRUKER ALPHA). Particle size 
distribution of the products were measured via DLS (DLS, Malvern 
Zetasizer Nano ZSP). Scanning Electron Microscopy (SEM, FEI 
NanoSEM 450, elemental composition by energy-dispersive X-ray 
analysis) was employed to analyse size and topography of particle 
and particle surface. Melting point analysis was performed using a 
Stuart Scientific SMP 3 instrument. Elemental analysis of 
nanoparticles was measured by Energy-Dispersive X-ray 
Spectroscopy). UV-vis spectroscopy (VARIAN 50 Probe UV-visible 
Spectrometer) was used to measure drug release from doxorubicin 
loaded polymer nanoparticles. The biocompatibility of the (loaded) 
polymers were measured via 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay / live-dead assay.
Copolymer molecular weights and molar mass dispersities were 
obtained by gel permeation chromatography (GPC) using an Agilent 
1260 instrument equipped with 2 x mixed-C columns plus guard 
column and a refractive index detector. DMF containing 1.0 w/v % 
lithium bromide (LiBr) was used as eluent at a flow rate of  1.0 mL 
min-1 and the temperature of the column oven and RI detector were 
set to 60 °C. A series of ten near-monodisperse poly(methyl 
methacrylate) standards (Mp ranging from 800 to 2,200,000 g mol-
1) were employed as calibration standards in conjunction with the RI 
detector for determining molecular weights.
Synthesis of Sarcosine NCA
Sarcosine NCA synthesis was conducted under a nitrogen 
atmosphere. 4.0 g of sarcosine and 14.0 mL of K")
 were added 
to 60.0 mL of anhydrous tetrahydrofuran (THF). 10.0 g of triphosgene 
was dissolved in 10.0 mL of anhydrous THF and added dropwise to 
the reaction mixture. The mixture was stirred under reflux at 60 °C 
for 4.5 hours. The appearance of the resulting solution was brown-
yellow. After rotary evaporation, brown precipitate and yellow 
solution were formed, before the products were stored under 
vacuum at 50 °C overnight. Consequently, brown solid formed that 
was dissolved in THF and added dropwise to cold n-hexane 
(recrystallisation). The recrystallisation procedure was performed 
two additional times before suction filtration was used to collect the 
products. The melting point was determined to be 104 °C  104.6 °C, 
which is in agreement with prior studies.29 
Polymerisation of Sarcosine NCA from N-Boc-ethylenediamine
0.80 g of sarcosine NCA was dissolved in 3.0 mL of anhydrous DMF, 
maintained under constant nitrogen flow. Then, 0.01 g of N-boc-
ethylenediamine hydrochloride was dissolved in 3.0 mL of anhydrous 
DMF before being added to the monomer solution. The 
polymerisation proceeded for four days until the products were 
isolated by polymer precipitation into 35 mL of cold diethyl ether. 
Polymer recovery has achieved by centrifugation for 30 minutes at 
4,000 rev/min. Finally the products were dried under vacuum at 
room temperature overnight.
Boc Cleavage from PSar-Conjugated N-Boc-ethylenediamine 
0.60 g of PSar-Conjugated N-Boc-ethylenediamine was dissolved in 
6.0 mL of TFA, and the reaction was stirred overnight at room 
temperature. The solution was then added dropwise to cold diethyl 
ether, to isolate the product, which was recovered by centrifugation 
at 4000 rev/min for 30 minutes. Finally the products were dried in a 
vacuum oven overnight.
SCPDB Conjugation to Amine-Bearing Polysarcosine
Under a nitrogen atmosphere, 0.025 g of SCPDB and 0.50 g of the 
deprotected PSar were independently dissolved in 1.0 mL and 12.0 
mL of anhydrous DCM, respectively.  The solution containing PSar 
was then added dropwise to the SCPDB solution, and the mixture 
stirred overnight. Consequently, the solution was added dropwise to 
cold diethyl ether, resulting in the formation of a pink solid, which 
was isolated by centrifugation for 30 minutes at 4000 rev/min and 
then dried in a vacuum oven overnight. The product was washed 
with DCM before a second recrystallisation was performed, prior to 
product isolation and drying overnight under vacuum. 
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HPMA Polymerisation from the PSar-macro-RAFT Agent
Absolute ethanol and deionised water underwent nitrogenation 
overnight. 0.40 g of the PSar-macro-RAFT agent was dissolved in 2.0 
mL of the absolute ethanol and followed by 30 minutes of 
ultrasonication. 0.015 g of APPH was dissolved in 10.0 mL of 
deionised water. Next, 0.082 g of the HPMA monomer was added to 
the macro-RAFT agent solution, before the AAPH solution, in addition 
to 3.0 mL of deionised water, were added. The mixture was stirred 
and stirred and degassed with nitrogen for 30 minutes before the 
mixture was heated in an oil bath for 4 hours at 55 °C. Every hour 1.5 
mL of the reaction mixture was removed from the polymerisation, 
and DLS analysis was performed. Finally, the product was dialysed for 
six days, freeze dried for 2 days and stored in a desiccator.
Results and discussion 
N-Boc-ethylenediamine was selected as a dual initiator for NCA ROP, 
and upon Boc group cleavage, RAFT polymerisation. The primary 
amine presented by the initiator enables the ROP of sarcosine NCA, 
yielding Boc group protected PSar (Scheme 1a).  Boc cleavage was 
achieved using TFA (Scheme 1b), yielding a range of homopolymers 
that contained PSar with chain lengths of 58 and 137 repeat units. 
The primary amine group liberated was used for RAFT agent (4-
cyano-4-(phenylcarbonothioylthio) pentanoic acid N-succinimidyl 
ester (SCPDB)) conjugation (Scheme 1c), before HPMA 
polymerisation was conducted in an ethanol/water mixture to yield 
a range of block copolymers (Scheme 1d).
Progress towards the desired block copolymers was monitored 
by FTIR (Figure S1). The secondary amide peak corresponding to PSar 
is present throughout the synthesis, but the ester peak attributed to 
the presence of the Boc protecting group (1227 cm-1) disappeared as 
expected upon Boc group cleavage. The grafting of the RAFT agent to 
polysarcosine resulted in the emergence of peaks representative of 
aromatic groups in the 900 cm-1 to 500 cm-1 region. The peak 
corresponding to the nitrile functional group is visible, however, this 
peak is very weak since there is designed to be only a single nitrile 
group per polymer chain. The FTIR spectrum of the final product, 
revealed the presence of the alcohol functional group (3486 cm-1, 
merged with secondary amine). The structures of all 
(macro)molecules formed were confirmed by 1H NMR spectroscopy 
(Figures S2-S17 and S20 -S23).
During each polymerisation, nanoparticle formation was tracked 
by DLS. Initially, two block copolymers (PSar58-b-PHPMA82 and    
PSar137-b-PHPMA273, where the number of repeat units represent 
complete monomer conversion to the final polymer after 4-hour 
polymerisation) were synthesised and examined (Table 1, DLS data 
presented in Figures S24 and S25). Nanoparticle sizes increased with 
time following a non-linear relationship, suggesting nanoparticle 
growth was mostly complete after approximately 3 hours. In 
addition, the particles became excessively large, with the exception 
of PSar137-b-PHPMA273 when polymerised for up to 2 hours. 
Consequently, it was decided that SCPDB conjugated to PSar (137 
repeat units) is a suitable macroinitiator for HPMA polymerisation, 
but the extent of HPMA polymerisation must be limited to yield 
desirable particles of less than 200 nm hydrodynamic diameter. A 
third block copolymer, PSar78-b-PHPMA130 after four hours 
polymerisation, was also produced and exhibited in situ particle 
formation during HPMA polymerisation (Table S1). However, this 
polymer was not progressed due to relatively large hydrodynamic 
diameters/PDI values obtained for the particles formed.  
Studies were undertaken whereby two target polymers, PSar136-
b-PHPMA53 and PSar136-b-PHPMA14, were produced over a 4-hour 
period, with polymer being isolated from the reaction vessel every 
hour. Polymer self-assembly by coacervation was undertaken and 
the nanoparticles formed analysed by DLS. Whilst PSar136 was unable 
to self-assemble to form nanoparticles in aqueous solution, SCPDB 
conjugation to PSar136 resulted in the formation of nanoparticles with 
a mean diameter of 114 nm and a PDI value of 0.454. Subsequent 
HPMA polymerisation from the macroinitiator resulted in the 
creation of nanoparticles of increased diameter (Table 2). 
Nanoparticle stability, in terms of both size and dispersity, is 
provided in Table 3 (particle diameter) and Table S2 (particle 
dispersity). The dimensions of many of the nanoparticle samples 
formed rendered many suitable candidates for use as potential drug 
delivery vehicles. Nanoparticles isolated from PSar136-b-PHPMA14 
and PSar136-b-PHPMA53 polymerisations after 2-hours were deemed 
the most appropriate to be advanced to Dox release studies. The 
structures of these polymers were found to be PSar136-b-PHPMA5 and 
PSar136-b-PHPMA21, respectively, as determined by 
1H NMR 
spectroscopy (Figures S16 and S17). The molecular weights and 
dispersity values of the polymers were found to be 11,600 g.mol-1 
and 1.26, respectively, for PSar136-b-PHPMA5, and 14,000 g.mol
-1 and 
1.07, respectively, for PSar136-b-PHPMA21, as determined by GPC.
 
SEM studies revealed the formation of discrete nanoparticles from 
PSar136-b-PHPMA5 and PSar136-b-PHPMA21 copolymers (Figure 2 and 
Figure S26, respectively). Energy dispersive X-ray analysis revealed 
the presence of sulfur only where particles were found, confirming 
the retention of the RAFT agent and successful polymerisation 
(Figure S27). 
Although the particles disclosed in this paper may readily be 
applied as materials that enable the controlled release of a range of 
molecular cargoes, the loading, and release, of an anticancer drug 
(Dox) into/from the particles was selected for further evaluation. The 
particles are deemed suitable candidates as drug delivery vehicles 
owing to their limited non-degradable polymer content, which is 
restricted to five repeat units on average per polymer chain in the 
case of PSar136-b-PHPMA5. Dox loading into polymer nanoparticles 
was achieved by dropping in a solution of polymer dissolved in DMF 
to vigorously stirred phosphate buffered saline (PBS) solution that 
contained Dox.30 97.9% (0.294 mg) of Dox added was loaded within 
2 mg of PSar136-b-PHPMA5 particles maintained in pH 7.4 solution 
and 96.8% (0.291 mg) of Dox added was loaded within 2 mg of 
PSar136-b-PHPMA5 added was loaded within 2 mg of PSar136-b-
PHPMA21 particles maintained in pH 7.4 solution and 96.5% (0.289 
mg) Dox added was loaded within 2 mg of particles maintained in pH 
5 solution. 97.2% (0.292 mg) of Dox added was loaded within 2 mg 
of PSar136-b-PHPMA21 particles maintained in pH 7.4 solution and 
96.5% (0.289 mg) Dox added was loaded within 2 mg of PSar136-b-
PHPMA21 particles maintained in pH 5 solution. PSar136-b-PHPMA5 
yielded Dox-loaded particles of 161 nm (PDI = 0.240) and PSar136-b-
PHPMA21 yielded Dox-loaded particles of 159 nm (PDI = 0.254). The 
PSar136-b-PHPMA5 particles were found to be stable when 
maintained in PBS buffer at 25 °C for at least 21 days, decreasing in 
hydrodynamic diameter insignificantly to 156 nm (PDI = 0.189, Table 
S3). PSar136-b-PHPMA5 particles stored in PBS buffer at 37 °C 
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decreased in hydrodynamic diameter from 130 nm to 129 nm after 
21 days (Table S4). However, in this instance a second peak formed 
over time that, after 21 days, was representative of particles that 
possess a hydrodynamic diameter of 31 nm and represented 6.1% of 
the total sample measured. The overall PDI of the sample was 
Table 1. Nanoparticle size and PDI values for nanoparticles formed in 
situ.
Duration PSar58-b-
PHPMA82 
(nm)
PDI PSar137-b-
PHPMA273 
(nm)
PDI
1 hour 393 0.409 129 0.326
2 hours 544 0.626 226 0.345
3 hours 554 0.174 365 0.306
4 hours 488 0.481 325 0.331
Table 2. Nanoparticle size and PDI values for nanoparticles formed 
from PSar136-b-PHPMA14 and PSar136-b-PHPMA53 following polymer 
coacervation.  
Duration PSar136-b-
PHPMA14
PDI PSar136-b-
PHPMA53
PDI
1 hour 144 0.176 149 0.129
2 hours 151 0.559 178 0.147
3 hours 247 0.336 195 0.058
4 hours 315 0.121 272 0.007
therefore relatively large (0.437), and indicates that Dox release 
occurs to a limited extent when PSar136-b-PHPMA5 particles are 
stored at 37 °C for extended periods. Dox release from PSar136-b-
PHPMA5 particles independently maintained in PBS solution (pH 7.4) 
and acetate buffer (pH 5) at 37 °C, under steady agitation, revealed 
that at 37 °C, both polymers released Dox slowly, with 20 % of Dox 
released from PSar136-b-PHPMA5 at pH 5 and 4 % of loaded Dox 
released from the same polymer after 18 days incubation at pH 7.4
Figure 2 a) Particle size determination of PSar136-b-PHPMA5 via DLS, 
b) SEM micrograph of PSar136-b-PHPMA5 nanoparticles. Scale bar 
represents 4 T c) Particle size determination and d) SEM images 
corresponding to Dox-loaded nanoparticles formed from PSar136-b-
HPMA5 that had been subjected to heating to 50 °C for 24 hours. 
Scale bar represents 4 T   
Scheme 1. The route to PSar-b-PHPMA. a) The synthesis of Boc protected PSar. b) Boc group cleavage to provide primary amine 
functionality to PSar. c) RAFT agent conjugation to PSar. d) RAFT polymerisation of HPMA from PSar. 
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Table 3 A comparison of stability of the nanoparticles formed upon 
polymer precipitation at hourly intervals during the synthesis of 
PSar136-b-PHPMA14 and PSar136-b-PHPMA53.  
Copolymer Target Size (nm)
PSar136-b-PHPMA14 After 24 
hours
After 14 
days
After 
21 days
1h 187 160 178
2h 207 135 156
3h 234 171 195
4h 284 271 293
PSar136-b-PHPMA53 After 24 
hours
After 14 
days
After 
21 days
1h 154 151 159
2h 197 140 148
3h 148 169 163
4h 288 276 288
(Figure 3). 10% (pH 5) and 2% (pH 7.4) of loaded Dox was released 
from PSar136-b-PHPMA21 after 18 days incubation (Figure S28).   
Greater Dox release occurred from nanoparticles stored in pH 5 
solution compared to those stored in pH 7.4 solution, which may be 
explained by the primary amine of Dox being protonated when in pH 
5 solution, enhancing the water solubility of the drug and aiding its 
release into acidic solution. 
Subsequent heating of both sets of nanoparticles to 50 °C was 
done to assess their thermoresponse. Enhanced Dox release (91% in 
pH 5 solution, 83% in pH 7.4 solution) of Dox from PSar136-b-PHPMA5 
particles occurred following re-assessment after a further 7 days of 
heating at the elevated temperature. PSar136-b-PHPMA21 particles 
also demonstrated enhanced Dox release upon heating at 50 °C, but 
in this case 30% (pH 5) and 16% (pH 7.4) of payload was released 
from the nanoparticles following re-assessment after 7 days of 
heating. The slower rate of Dox release from PSar136-b-PHPMA21 may 
Figure 3 Doxorubicin release from PSar136-b-PHPMA5 at pH 5 and pH 
7.4.
Table 4. A comparison of Dox loaded and unloaded PSar136-b-
PHPMA5 nanoparticle sizes at room temperature 37 °C, and 50 °C. 
be assigned to the increased length of the thermoresponsive PHPMA 
section within the composition. Altering the PHPMA block length to 
manipulate drug release extent/rate is a feature that may be further 
exploited. The critical temperature at which Dox release from 
PSar136-b-PHPMA5 nanoparticles is triggered was then determined. 
Initially, DLS studies revealed that the size of unloaded nanoparticles 
did not change significantly upon increasing the solution 
temperature from 25 °C (166 nm) to 37 °C (164 nm) (Table 4). Upon 
increasing the temperature to 50 °C, the particle size decreased to 
132 nm. All PDI values for the unloaded nanoparticles were less than 
0.3, signifying that the nanoparticles were stable at room 
temperature, 37 °C and 50 °C. PSar136-b-PHPMA5 nanoparticles 
loaded with Dox had a hydrodynamic diameter of 161 nm in aqueous 
solution at 25 °C. The Dox-loaded nanoparticle size decreased from 
161 nm to 130 nm as the temperature was increased to 37 °C. Upon 
further solution temperature increase to 50 °C, the particle size 
decreased further to 91 nm. This dramatic decrease in nanoparticle 
diameter, and the consequent expulsion of Dox from the 
nanoparticles, is proposed to be the reason for extensive Dox release 
at 50 °C. The PDI values of the Dox-loaded nanoparticles at 37 °C 
(0.389) and 50 °C (0.468) were above 0.3; such instability is likely to 
be due to the release of Dox. 
The change in the morphology of the nanoparticles that 
contained Dox could clearly be evidenced by SEM analysis, after
Figure 4. The temperature-dependent release of Dox from PSar136-b-
PHPMA5 nanoparticles upon incremental solution temperature 
increase.
Polymer Size 
(nm)
PDI
PSar136-b-PHPMA5 without doxorubicin 
loaded at room temperature
166 0.218
At 37 °C 164 0.261
At 50 °C 132 0.215
PSar136-b-PHPMA5 with doxorubicin loaded 
at room temperature
161 0.240
At 37 °C 130 0.389
At 50 °C 91 0.468
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heating the nanoparticles to 50 °C for 24 hours (Figure 2d). Less 
spherical, more elongated, particles were observed by SEM analysis, 
further confirming that a thermally-induced nanoparticle transition 
had occurred. Smaller particles (34 nm) were observed in post- 
heated samples that may be assigned to be released Dox aggregates.
The release of Dox from PSar136-b-PHPMA5 nanoparticles was then 
monitored in response to incremental PBS solution temperature 
increases whereby the solution temperature was raised by 1 °C, the 
solution was maintained at the increased temperature for 24 hours, 
and the amount of Dox released at the increased temperature was 
measured (Figure 4). Dox release occurred slowly and steadily to 16 
% as the solution temperature was increased from 25 °C to 39 °C over 
360 hours. At this point the percentage of Dox released increased 
markedly to 78 % at 41 °C, signifying that the critical temperature for 
Dox burst release, and that the likely solution glass transition 
temperature of the hydrated block copolymer is between 39 °C and 
41 °C. A more detailed study in which the loaded nanoparticles were 
monitored at 40 °C for 24 hours confirmed that 62.4% Dox release 
was achieved by heating the nanoparticles to 40 °C for 24 hours 
(Figure S29). This offers validation that the reported nanoparticles 
are pharmacologically relevant; payload release can be actuated by 
nanoparticle heating to a temperature that is not detrimental to cell 
survival.  
Pharmacological studies were undertaken whereby the 
cytotoxicity of the nanoparticles formed from PSar136-b-PHPMA5 
were assessed on MCF-7 breast cancer cells, triple-negative breast 
cancer cells (MDA-MB-231), and Her2-enriched (ER and PR negative) 
breast cancer cells (MDA-MB-453), to assess the capability of the 
materials to potentially treat chemo-refractory disease. Free Dox 
was used as a positive control (Tables S5 and S6). In all instances, the 
polymer nanoparticles were found to cause negligible cell death at 
both 37 °C and at 41 °C, validating the non-cytotoxicity of the 
polymers produced (Figure 5). Dox-loaded nanoparticles were then 
assessed against the three same cell lines; in each instance 
pronounced cell death occurred that became progressively greater 
with enhanced polymer concentration. It may be hypothesised that 
the nanoparticles are of sufficiently small dimensions to undergo 
endocytosis both at the lower and elevated temperature, and that 
Dox leakage from the nanoparticles is sufficiently significant to cause 
cell death following nanoparticle uptake.
Conclusions
Combining NCA ROP and RAFT polymerisation is a viable 
route to the creation of amphiphilic block copolymers that are 
thermoresponsive. The synthesis of a PSar-b-PHPMA in a 
water/ethanol mixture leads to the in situ formation of 
particles, as assessed by DLS. Using DLS in this manner enables 
the elucidation of the ideal composition of PSar-b-PHPMA for 
the creation of suitably sized, stable, nanoparticles for 
controlled release applications. Modifying PSar with a very 
moderate amount of PHPMA has a profound effect on the 
copolymer formed, which is capable of thermoresponsive 
nanoparticle formation in aqueous solution. PSar136-b-PHPMA5 
self-assembly in the presence of Dox yields drug-loaded 
nanoparticles, and Dox release from the nanoparticles can be 
actuated by an increase in environmental temperature to 41 °C. 
Such nanoparticles are non-cytotoxic against the three breast 
cancer cell lines tested, in contrast to Dox-loaded nanoparticles 
which instigated pronounced cell death in each case. 
Consequently, the nanoparticles disclosed have potential 
Figure 5. Cytotoxicity of PSar136-b-PHPMA5 either empty (polymer 
only) or loaded with doxorubicin (dox polymer) on three breast 
cancer cell lines.  Serial dilutions of polymer or dox polymer were 
incubated with MCF-7, MDA-MB-231 (triple negative) or MDA-MB-
453 (double negative) cell lines for 72 hours either with or without 
incubation of the cells at 41 °C for 40 minutes within the first hour of 
incubation.  Graphs of the mean and standard deviation from 3 
independent experiments are fitted with a four parameter log 
inhibitor curve.
application for the thermally-triggered release of guest 
molecules to external solution, and the encapsulation, 
distribution, and release of Dox to breast cancer cells as a mode 
of therapeutic delivery.
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